Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway.
Br J Cancer
; 130(4): 513-516, 2024 03.
Article
in En
| MEDLINE
| ID: mdl-38316994
ABSTRACT
The "undruggable" MYC oncoproteins are deregulated in 70% human cancers. The approval of DFMO, an irreversible inhibitor of ornithine oxidase (ODC1) that is a direct transcriptional target of MYC, demonstrates that patients can benefit from targeting MYC activity via an indirect approach. However, the mechanism of action of DFMO needs further studies to understand how it works in post-immunotherapy neuroblastomas. Efforts to develop a more potent and safer drug to block MYC function will continue despite challenges.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neuroblastoma
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Br J Cancer
/
Br. j. cancer
/
British journal of cancer
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: